FORMING STATIN RESPONSE IN PATIENTS WITH CORONARY HEART DISEASE IN PRESENCE OF ACUTE RESPIRATORY VIRAL INFECTIONS BY MEANS OF GENETIC MARKERS
Introduction: The present study evaluated the interaction of statin response and genetic polymorphism of interleukin (IL-1β, IL-6, IL-4,IL-10) genes with the course of atherosclerosis and coronary heart disease (CHD) in patients with CHD combined with acute respiratory viral infections (ARVI).
Objectives: Studying variability of Rosuvastatin response in patients with CHD combined with ARVI, taking cytokine gene polymorphism into account.
Materials and Methods: Detection of lipid metabolism parameters and interleukin levels in blood serum; verification of causative agents of the infectious process. Genotyping of polymorphisms IL-1β –511C>T, IL-6 –174G>C, IL-4 –589C>T, IL-10 –1082G>А. Statistical processing in Microsoft Office Excel 2007 software.
Results and Discussion: In CHD patients at Visit I, the target level of low-density lipoprotein cholesterol (LDL-C) was reached by 55.7% of participants. At Visit II, the target LDL-C level was reached by 49.7% of patients, which coincided with ARVI detection in some patients.
In CHD patients with ARVI at Visit II, the IL-1β level increased to 33.00 pg/ml (N=5.00 pg/ml), IL-6 – 19.20 pg/ml (N=9.00 pg/ml); at Visit VI those levels decreased to 20.70 pg/ml and 12.80 pg/ml. The IL-4 level was 8.30 pg/ml (N=13.00 pg/ml), while IL-10 level was 19.40 pg/ml (N=31.00 pg/ml), with their increase at Visit VI to 15.80 pg/ml and 33.50 pg/ml.
CHD patients without ARVI did not develop interleukin level changes. At Visit II, the IL-1β level was 10.30 pg/ml, IL-6 level was 12.40 pg/ml, and at Visit VI, they were 13.00 pg/ml and 14.00 pg/ml. The IL-4 and IL-10 levels at Visit II were 19.70 pg/ml and 32.30 pg/ml; at Visit VI, those levels were 23.20 pg/ml and 34.20 pg/ml. The following associations were demonstrated: –511CT / increased IL-1β, LDL-C synthesis; –511СС / LDL-C level increase; –174GG / IL-6, LDL-C level increase; –1082GG / IL-10 level increase, cholesterol and CRP level decrease; –589ТТ / CRP, IL-4 level increase.
Conclusion: Genotypes –511CT, –174GG, –1082AA in all patients required 20 mg/day Rosuvastatin dose to reach the target LDL-C level.